Group 1 - The core viewpoint of the report is that Pacific Securities maintains a "Buy" rating for Universal Medical (02666.HK), forecasting significant revenue and profit growth from 2025 to 2027, with projected revenues of 14.72 billion, 15.34 billion, and 16.25 billion yuan, and net profits of 2.12 billion, 2.23 billion, and 2.37 billion yuan respectively [1] - The expected EPS for the same period is 1.12, 1.18, and 1.25 yuan, with corresponding PE valuations of 4.99, 4.75, and 4.47 times based on the closing price on October 29 [1] - The company’s healthcare business is identified as a core growth engine, while its financial business remains stable with effective risk control, enhancing the overall value of the company [1] Group 2 - Universal Medical has a market capitalization of 11.576 billion HKD, ranking 5th in the healthcare services II industry [2] - Key performance indicators show a ROE of 12.39%, a net profit margin of 17.61%, and a debt ratio of 73.38%, which are competitive compared to the industry averages [2] - The company’s revenue of 14.701 billion HKD is significantly higher than the industry average of 3.832 billion HKD, indicating strong market positioning [2]